Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Invested Capital Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -82.39%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -97.49%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -79.34%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 61.45%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -7.15%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1,178.57%
10 Vanda Pharmaceuticals 379.35 Mn 177.04 Mn 48.56 Mn -64.00%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -64.00%
Dec 31, 2025 -2,555.56%
Sep 30, 2025 -322.22%
Jun 30, 2025 -475.00%
Mar 31, 2025 -614.29%
Dec 31, 2024 -80.00%
Sep 30, 2024 -3,878.18%
Jun 30, 2024 -366.67%
Mar 31, 2024 -216.67%
Dec 31, 2023 -141.67%
Sep 30, 2023 -96.03%
Jun 30, 2023 -40.00%
Mar 31, 2023 154.55%
Dec 31, 2022 0.00%
Sep 30, 2022 -57.14%
Jun 30, 2022 -70.59%
Mar 31, 2022 -173.33%
Dec 31, 2021 -20.00%
Sep 30, 2021 27.27%
Jun 30, 2021 6.25%
Mar 31, 2021 1,400.00%
Dec 31, 2020 87.50%
Sep 30, 2020 -94.02%
Jun 30, 2020 -23.81%
Mar 31, 2020 200.00%
Dec 31, 2019 -57.89%
Sep 30, 2019 1,315.38%
Jun 30, 2019 133.33%
Mar 31, 2019 -116.67%
Dec 31, 2018 575.00%
Sep 30, 2018 230.00%
Jun 30, 2018 400.00%
Mar 31, 2018 135.29%
Dec 31, 2017 -247.60%
Dec 31, 2016 96.74%
Dec 31, 2015 -119.91%
Dec 31, 2014 869.57%
Sep 30, 2014 76.47%
Jun 30, 2014 -481.82%
Mar 31, 2014 -426.67%
Dec 31, 2013 0.00%
Sep 30, 2013 10.53%
Jun 30, 2013 60.71%
Mar 31, 2013 46.43%
Dec 31, 2012 -15.00%
Sep 30, 2012 -72.73%
Jun 30, 2012 -460.00%
Mar 31, 2012 -6,057.58%
Dec 31, 2011 -385.71%
Sep 30, 2011 -200.00%
Jun 30, 2011 -225.00%